Alacris Theranostics participates in a number of national and international research projects:

CanPathPro
Alacris Theranostics co-ordinates this Horizon 2020 funded project aimed at developing a combined experimental and systems biology platform for predictive modelling of cancer signalling.
PROSEQO PROSEQO
A FET-OPEN (Horizon 2020) project, aimed at developing novel proof-of-principle technologies for high-throughput protein sequencing and single molecule DNA/RNA sequencing.
SMARTool
Horizon 2020 funded project aimed at developing IT solutions to support clinicians in the prevention and treatment of heart disease.
TREGeneration TREGeneration
As part of the Horizon 2020 programme the European consortium carries out a clinical research project for the treatment of Graft versus Host Disease, a serious complication following bone marrow transplantation.
CANCER-ID Cancer ID
A European consortium funded by the Innovative Medicines Initiative (IMI) with currently 33 partners from 13 countries aiming at the establishment of standard protocols for and clinical validation of blood-based biomarkers.
EPITREAT EPITREAT
A German Federal Ministry of Education and Research funded project focused on developing personalised lung cancer treatment based on epigenetic biomarkers.
SYBIL SYBIL
A large-scale inter-disciplinary consortium aimed at functional validation of genetic determinants of common and rare skeletal diseases. Results generated will enhance the mechanistic understanding of disease processes and age-related changes, and deliver new and validated therapeutic targets.
Treat20plus Treat20plus
Applying a systems biology approach to predicting treatment outcome in metastatic skin cancer patients. Funded by the German Federal Ministry of Education and Research.
Logo-OncoTrack-180 OncoTrack
An international consortium of over 80 scientists that has launched one of Europe’s largest collaborative academic-industry research projects, focused on developing and validating biomarkers to provide a personalised approach to the treatment of colon cancer; a goal driven by a systems medicine approach based on in silico “Virtual Patient” models.


Collaborators:


Funding:

Alacris is among the top 5 SMEs based on funding FP7. Please scroll to page 5 of the following report for more details.

Download (PDF, Unknown)